NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services ...
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter ...
NeoGenomics announced preliminary double-digit revenue growth for the fourth quarter and full year of 2025. The cancer testing company projects total 2025 revenue of about $727 million, a 10% increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results